The effects of 89Sr treatment on the natural host resistance of CD-1 mice and the enhancement of resistance by immunomodulators to infection with Listeria monocytogenes or herpes simplex virus type 2 (HSV-2) were determined. In the CD-1 mouse, single-dose treatment with 89Sr caused a profound decrease in the number of circulating monocytes (Mo), lymphocytes, and polymorphonuclear leukocytes (PMN) within 1 week. (7, 16, 21) . These methods have been useful, but all suffer from some nonspecificity, short depletion period, or both. We have been investigating injection of the bone-seeking isotope 89Sr into mice, which results in concentrated irradiation and subsequent destruction of bone marrow cells (1, 6, 9 ). An experimental system is thereby provided which appears to offer a more selective means and longer period of suppression in which to study the origins, maturational requirements, and interrelationships of defined bone marrow cell populations. Through the use of 89Sr, it has been demonstrated that the generation of NK cells is an autonomous function of the bone marrow (8) and that a normal bone marrow microenvironment is required for the maturation of NK cells into effective cytotoxic cells (10, 17) . 89Sr also appears to be an effective means for investigating M4 heterogeneity, because resident alveolar and peritoneal M4 populations are sustained for at least 1 month after 89sr treatment, while Mo levels in blood fall profoundly within * Corresponding author. 72 h (26, 28, 30) . The simultaneous effects of 89Sr treatment on the mononuclear phagocyte and NK cell populations, however, has not been established, because various 89Sr regimens and mouse strains have been used in these studies directed at Mo or NK cells separately. In this paper we report longitudinal studies that follow changes in both nonspecific effector cell populations.
This study was designed to assess the contributions of natural killer (NK) cells, monocyte (Mo) macrophages (MO), and tissue MX to natural and immunomodulator-enhanced antimicrobial resistance. Immunomodulators often activate both mononuclear phagocytes and NK cells; thus, it is difficult to assess their relative contributions to enhanced resistance (21, 25) . A variety of cell depletion methods have been used, such as treatment of mice with radiation, agents toxic for macrophages, or antisera specific for NK cells (7, 16, 21) . These methods have been useful, but all suffer from some nonspecificity, short depletion period, or both. We have been investigating injection of the bone-seeking isotope 89Sr into mice, which results in concentrated irradiation and subsequent destruction of bone marrow cells (1, 6, 9 ). An experimental system is thereby provided which appears to offer a more selective means and longer period of suppression in which to study the origins, maturational requirements, and interrelationships of defined bone marrow cell populations. Through the use of 89Sr, it has been demonstrated that the generation of NK cells is an autonomous function of the bone marrow (8) and that a normal bone marrow microenvironment is required for the maturation of NK cells into effective cytotoxic cells (10, 17) . 89Sr also appears to be an effective means for investigating M4 heterogeneity, because resident alveolar and peritoneal M4 populations are sustained for at least 1 month after 89sr treatment, while Mo levels in blood fall profoundly within 72 h (26, 28, 30) . The simultaneous effects of 89Sr treatment on the mononuclear phagocyte and NK cell populations, however, has not been established, because various 89Sr regimens and mouse strains have been used in these studies directed at Mo or NK cells separately. In this paper we report longitudinal studies that follow changes in both nonspecific effector cell populations.
The few studies using 89Sr administration to probe the antimicrobial functions of bone marrow-dependent cells have revealed striking differences, depending on the microbial infection and the genetic background of the mice used (2, 3, 13, 15, 20, 27 Strontium. Radioactive 89Sr with specific activity greater than 100 mCi/g of Sr was purchased from Amersham Corp., Arlington Heights, Ill. For a few experiments, 89Sr with a specific activity of greater than 6,000 Ci/g of Sr was purchased from Oak Ridge National Laboratory, Oak Ridge, Tenn. Mice were inoculated intravenously or intraperitoneally (i.p.) with 89Sr (4 ,uCi/g of body weight); no significant differences were apparent with respect to the route of administration. Control groups consisted of mice that were injected with either 0.87% physiological saline or nonradioactive 89Sr at the same concentration (in milligrams per kilogram) as the carrier 88Sr in the radioactive 88Sr. No significant differences with respect to the substance injected were apparent between the two control groups. Experiments were performed at both The Medical College of Pennsylvania and East Carolina University School of Medicine; analysis of variance revealed no significant differences between the data from the two sites, and experimental data therefore were treated as being from one source. The regimens of 89Sr administration are referred to as (i) single-dose 89Sr administration, or (ii) double-dose 89Sr administration, which indicates that a second injection of 89Sr was made approximately 1 month after the first injection. This prevented any recovery of bone marrow due to reduced radioactivity of the 89Sr, which has a half-life of 50.4 days.
Analysis of peripheral blood cells and peritoneal cells. Experimental groups generally consisted of five to seven mice. Individual mice were anesthetized with ether, and blood was obtained from the retroorbital plexus or the tail vein. Leukocyte counts were obtained with a cell counter (ZM or D; Coulter Electronics, Hileah, Fla.). Leukocytes were prepared for differential counts by removing erythrocytes in heparinized 3% dextran (blood-dextran [1:3] , by volume) and washing the layer of concentrated leukocytes by centrifugation at 200 x g. Cytocentrifuge slides (Cytospin; Shandon-Southern, Sewickley, Pa.) were prepared from the leukocyte concentrates and stained with Dif-Quik stain (Fisher Scientific Co., Pittsburgh, Pa.) or May-Gruenwald Giemsa stain; at least 200 cells were counted to establish a differential count.
After mice had been exsanguinated, peritoneal cells (PC) were obtained by lavage with 5 ml of heparinized (2 U/ml) phosphate-buffered saline as described previously (30) . Total and differential cell counts were prepared as described above for leukocyte counts.
Total and absolute counts of nucleated cell classes were determined by multiplying the percentage of each cell class found on the differential counts by the concentration of total leukocytes or PC in the individual mouse. To compare the effect of treatment of mice with 89Sr or immunomodulators, the value for each treatment group was calculated as a percentage of the average value for the control group determined on the same day. Comparisons between the treatment groups and control groups were analyzed by a two-way analysis of variance.
Determination of ectoenzyme phenotypes. Pools of PC were plated at concentrations to give approximately 2 x 106 in 35-mm-diameter plastic petri dishes. MX were allowed to adhere for 2 h at 37°C, and the nonadherent cells were removed by vigorous washing. The M4were then lysed in 0.05% Triton X-100; and the cell lysates were frozen at -20°C and assayed for protein, 5'-nucleotidase, alkaline phosphodiesterase I, and leucine aminopeptidase ectoenzyme activities as described previously (22) . All enzyme activities are expressed as nanomoles of product formed per minute per milligram protein at 37°C. M+-activating agents. Mice were injected i.p. with 0.5 ml of aged Brewer thioglycolate (TG) broth (10%) 5 days prior to harvest of PC. C. parvum (Burroughs Wellcome Co., Research Triangle Park, N.C.) was injected into mice i.p. at 35 mg/kg 7 days prior to the harvest of PC or the infection of mice. Maleic anhydride-divinyl ether (MVE-2; courtesy of D. Breslow, Hercules, Inc., Wilmington, Del.) was dissolved in phosphate-buffered saline, to provide a final inoculation concentration of 50 mg/kg i.p. and was inoculated into mice 1 day prior to microbial infection (18) . Avridine (CP20,961; courtesy of A. R. Kraska, Pfizer Inc., Groton, Conn.) was obtained as a preparation in dimyrysterolphosphatidyl choline liposomes. The drug was inoculated i.p. at 50 mg/kg 1 day prior to microbial infection (23) .
Microbial infections. A pool of the MS strain of HSV-2 was prepared in HEp2 cells as described previously, and titrated for PFU on Vero cells (19) . A pool of L. monocytogenes 29303, serotype 4b, was grown in Trypticase (BBL Microbiology Systems, Cockeysville, Md.) soy broth as described previously and titrated for CFU on blood agar plates (18) . All pools were dispensed into small fractions and frozen at -70°C. For the antimicrobial protection experiments, groups of six to eight mice were treated with active agents or placebo and infected with 10-fold dilutions of the microorganism. Generally, four to five dilutions were used. Mortality was monitored daily for the percent mortality, and survival distribution at different microbial challenge levels was calculated. The 50% lethal dose (LD50) was also calculated. Mortality at a given dilution was analyzed by the chi-square test with the Yates correction factor, and the survival distribution was analyzed by the Mann Whitney U test. RESULTS
Effects of "Sr on the long-term kinetics of effector cell populations. The effects of both single-and double-dose administration of 89Sr (see above) were followed for 72 days. NK Cells. The present data revealed that the CD-1 mouse strain has a low spontaneous NK cell activity, with an average cytotoxicity of 11.8% + 1.3 (standard error of the mean) at an effector-to-target cell ratio of 200:1 and that treatment with 89Sr reduced this activity to negligible levels within 1 week (Fig. 1) . Equally rapid reduction occurred with 89Sr with a specific activity in the range of 70 to 120 mCi/g or 6,000 Ci/g. In other mouse strains (e.g., C57B1/6) with high spontaneous NK cell activity, both higher specific activity of 89Sr and longer treatment times appear to be necessary for NK cell depression (unpublished data). There was partial recovery of NK cell activity in CD-1 mice by about 50 days, which was aborted when mice received a second injection of 89Sr at 30 days. Treatment with 89Sr did not significantly decrease spontaneous natural cytotoxic cell activity against EL-4 target cells for at least 30 days after treatment with 89Sr (data not shown). Treatment with interferon did not restore NK activity throughout the entire experimental period (Fig. 1) (Fig. 2) . Mo recovered more gradually, with the population approaching near normal levels by about day 60. Recovery of both populations was prevented by a second administration of 89Sr.
PC. There was relatively little effect on the sizes of peritoneal MX and lymphocyte (Ly) populations in CD-1 mice for at least 30 days after administration of 89Sr (20, 30) .
The long-term kinetics data from this study demonstrate marked changes after that time, with a distinct decline in Ly and a gradual decline in M4 (Fig. 3) . The decline in perito- Between days 63 and 72 after treatment with 89Sr, the resident peritoneal M41 population was significantly depressed to approximately 50% of the levels in age-matched controls, in the face of rising Mo counts (Fig. 2) (12, 14) . Approximately 104 CFU of L. monocytogenes and 103 PFU of HSV-2 were required to produce an LD50 (Tables 2 through 4 ). Moreover, despite the profound decrease in circulating Mo and PMN and in NK cell activity during the first 30 days after treatment with 89Sr, there was little change within this time period between the splenic titer or the LD50 for L. monocytogenes or HSV-2 in normal CD-1 mice and in mice treated with 89Sr (Tables 2  through 4) .
Mice were treated with C. parvum 3 to 5 days after single-dose 89Sr treatment and infected with L. monocytogenes 7 days later. Treatment with C. parvum, whether in normal mice or 89Sr-treated mice, significantly enhanced resistance (Table 2 ). L. monocytogenes growth in the spleen was reduced at least 4 log10, and there was approximately a 100-fold increase in resistance in both 89Sr-treated and control mice.
Prophylactic treatment with the synthetic immunomodulators MVE-2 or avridine in liposomes 1 day prior to infection with HSV-2 was also effective in mice treated with a single dose of 89Sr. At least 100-fold more virus was required to produce an LD50 in MVE-2-treated mice as compared with that in untreated mice, whether the mice were treated with 89Sr or not ( Table 3 ). The median survival time of mice treated with MVE-2 also increased significantly. In 89Sr-treated mice, NK cell activity was decreased and not activatable with interferon, whether mice were treated with MVE-2 or the saline placebo. Treatment with the lipoidal amine avridine in liposomes was also effective against HSV-2 infection in normal mice and in mice treated with 89Sr (Table  4) . Mortality was significantly reduced, and the median survival time of mice increased comparably in the two groups. DISCUSSION Our data show that the CD-1 mouse is uniquely suitable for nonspecific effector cell depletion studies, because with the use of 89Sr it is possible to achieve an early and profound depression of both blood Mo and NK effector cell populations, without apparent impairment of the resident peritoneal M+. The CD-1 mouse thus differs from other mouse strains, in which it is not possible to achieve early depression of both effector cell populations. With the CD-1 mouse, treatment with 89Sr ranging in specific activity from 70 to 6 x 106 mCi/g appears to produce comparable effects on the effector cell populations and natural host resistance. Moreover, the alterations in effector cells persist for at least 50 days, unlike those obtained by many other depletion methods (7, 16, 21) . Results of our studies have established that despite profound monocytopenia, granulocytopenia, and depressed NK cell functions, the CD-1 mouse expresses relatively normal natural resistance to three diverse microbial infections: encephalomyocarditis virus (20), L. monocytogenes (Table  2) , and HSV-2 (Tables 3 and 4) . The results of this study have also documented that prophylactic treatment of the CD-1 mouse with various immunomodulators (C. parvum, the synthetic polyanionic copolymer MVE-2, and the lipoidal amine avridine) produces comparable activity in normal and Mo-and NK cell-depleted mice. Preliminary data on therapeutic treatment of mice with either purified natural murine alpha and beta interferon or human alpha A/D recombinant interferon have also revealed significantly prolonged survival against encephalomyocarditis virus in normal and 89Sr-treated mice.
Our data and those obtained in other mouse strains (10) indicate that the immunomodulators do not restore the depressed NK cell activity in the 89Sr-treated mouse while they produce normal enhancement of some activated M4 functions (20, 30) . Results of previous work by us and others inflammation in control animals infected with encephalomyocarditis virus, and there is no apparent inflammation in 89Sr-treated and infected mice (unpublished data). The extent of possible 89Sr-induced changes in functions among resident tissue M4 populations has not been completely established. A distinct alteration after 89Sr administration occurs in the spleen in which suppressor M4) can no longer be induced by C. parvum treatment (Y. Shibata and A. Volkman, J. Immunol., in press).
The results of this study are the first indication that there may be long-term effects of 89Sr administration on the normal regulation of the resident M4f population. Resident peritoneal M4 in CD-1 mice were maintained in 89Sr-treated mice at a level of approximately 4 x 106 M( per mouse between 7 and 70 days after one treatment with 89Sr, while there was an age-related increase in M4 (24) in controls. These effects may result from cumulative absorption of low-level radiation in soft tissues (4) or from the regulation of the number of cells in the peritoneal cavity by body size. Mice treated with high specific activities of 89Sr (6,000 Ci/g) appear to grow more slowly than their controls (unpublished data). A relatively slow turnover of resident M4 could also result in the changes that were observed late in the experiment. However, the half-time for resident M0 in the peritoneal cavity appears to be less than 30 days (5, 26, 29) , so that the readily detectable and earlier decline in resident M4 that should have occurred in the precursor pool occurred immediately when they were destroyed by 89Sr. It is noteworthy that the steepest decline in the resident MX was seen at the late intervals, when Mo levels were returning to normal levels in the single-dose 89Sr treatment regimen. These observations add additional support for the view that resident M4 are not immediately derived from blood Mo and that these populations may be independently regulated. In view of the late changes in the resident peritoneal M( population, it would be of interest to determine the effects of double-dose 89Sr treatment on host resistance and other important M, populations in tissues. Our initial results suggest that natural resistance of the CD-1 mouse to L. monocytogenes may be decreased after double-dose 89Sr treatment, because there was a 93-fold decrease in the number of bacteria required to produce the LD50 in the 89Sr-treated mice. In contrast, there was not a marked decline in the natural resistance that CD-1 mice exhibited to HSV-2; the LD50 was 102.9 PFU in normal mice and 102.5 PFU in 89Sr-treated mice.
